Negative Prognostic Relevance Of A Specific 3-Gene Cluster In Myelodysplastic Syndromes During Azacitidine And Lenalidomide Therapy

BLOOD（2018）

引用 0|浏览10

暂无评分

摘要

Background and Rationale. Azacitidine (AZA) is a standard first-line therapy in high-risk MDS. Also its combination with Lenalidomide (LEN) has been tested, but its molecular effect is still under investigation. Here we analyzed the effect of AZA+LEN therapy on gene mutations and microRNA expression in MDS patients.

查看译文

关键词

Lenalidomide,Azacitidine,Myelodysplastic syndromes,Cancer,Gene cluster,Oncology,microRNA,Medicine,Complete remission,Internal medicine,Lenalidomide therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要